Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells
Titel:
Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells
Auteur:
Laterza, M.M. Ciaramella, V. Morgillo, F. Belli, V. Petrillo, A. Tirino, G. Pompella, L. Savastano, B. Pappalardo, A. Orditura, M. Ciardiello, F. De Vita, F.